Kaji, Reiko

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 178

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Urata, Y., Katakami, N., Morita, S., Kaji, R., Yoshioka, H., Seto, T., Satouchi, M., Iwamoto, Y., Kanehara, M., Fujimoto, D., et al. (2016) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 159

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR ‐mutant non–small cell lung cancer: Multicenter, single‐arm, phase 2 trial (ABC Study)

Hata, A., Katakami, N., Kaji, R., Yokoyama, T., Kaneda, T., Tamiya, M., Inoue, T., Kimura, H., Yano, Y., Tamura, D., et al. (2018) · Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 42